{
    "clinical_study": {
        "@rank": "117518", 
        "arm_group": [
            {
                "arm_group_label": "Subject 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side."
            }, 
            {
                "arm_group_label": "Subject 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side."
            }, 
            {
                "arm_group_label": "Subject 3", 
                "arm_group_type": "Active Comparator", 
                "description": "Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side."
            }, 
            {
                "arm_group_label": "Subject 4", 
                "arm_group_type": "Active Comparator", 
                "description": "Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side."
            }, 
            {
                "arm_group_label": "Subject 5", 
                "arm_group_type": "Active Comparator", 
                "description": "Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side."
            }, 
            {
                "arm_group_label": "Subject 6", 
                "arm_group_type": "Active Comparator", 
                "description": "Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer  at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side."
            }
        ], 
        "brief_summary": {
            "textblock": "Up to 6 subjects will be enrolled. Subjects who have already chosen to have a surgical\n      facelift procedure will be enrolled.  Subjects will receive selective Ulthera\u00ae ultrasound\n      exposures in the pre-auricular regions. Subject will return for a follow-up visit up to 48\n      hours post-treatment, on the day of their rhytidectomy. Study images will be obtained\n      pretreatment, immediately post-treatment, and at the follow-up visit."
        }, 
        "brief_title": "Feasibility Study: Histological Characterization After Treatment With the Ulthera\u00ae System", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Skin Laxity", 
        "condition_browse": {
            "mesh_term": "Cutis Laxa"
        }, 
        "detailed_description": {
            "textblock": "This study is a prospective, single-center clinical trial.  Subjects will be enrolled at the\n      investigator's discretion if they meet inclusion/ exclusion criteria and provide written\n      informed consent.  Enrolled subjects will be treated with an assigned transducer based on\n      their order of enrollment. At the study follow-up visit, subjects will undergo resection of\n      the treated tissue for histological analysis prior to their planned rhytidectomy procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 30 to 65 years  scheduled for rhytidectomy.\n\n          -  Subject in good health.\n\n          -  Understands and accepts the obligation not to undergo any other procedures in the\n             areas to be treated.\n\n          -  Willingness and ability to comply with protocol requirements, including returning for\n             follow-up visits and abstaining from exclusionary procedures for the duration of the\n             study.\n\n          -  Subjects of childbearing potential must have a negative urine pregnancy test result\n             and must not be lactating at Visit 1 and be willing and able to use an acceptable\n             method of birth control (e.g., barrier methods used with a spermicidal agent,\n             hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women\n             will not be considered of childbearing potential if one of the following conditions\n             is documented on the medical history: a) Postmenopausal for at least 12 months prior\n             to study; b) Without a uterus and/or both ovaries; or c) A bilateral tubal ligation\n             at least six months prior to study enrollment.\n\n        Exclusion Criteria:\n\n          -  Presence of an active systemic or local skin disease that may affect wound healing.\n\n          -  Severe solar elastosis.\n\n          -  Significant scarring in areas to be treated.\n\n          -  Open wounds or lesions in the area to be treated.\n\n          -  Severe or cystic acne on the area to be treated.\n\n          -  Presence of a metal stent or implant in the facial area to be treated.\n\n          -  Inability to understand the protocol or to give informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713569", 
            "org_study_id": "ULT-122"
        }, 
        "intervention": {
            "arm_group_label": [
                "Subject 1", 
                "Subject 2", 
                "Subject 3", 
                "Subject 4", 
                "Subject 5", 
                "Subject 6"
            ], 
            "description": "Focused ultrasound energy delivered below the surface of the skin", 
            "intervention_name": "Ulthera Treatment", 
            "intervention_type": "Device", 
            "other_name": "Ultherapy\u2122"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ulthera\u00ae System", 
            "Ultherapy\u2122 Treatment", 
            "Ulthera, Inc.", 
            "Ultrasound treatment for skin tightening"
        ], 
        "lastchanged_date": "November 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pasadena", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91105"
                }, 
                "name": "Sasaki Advanced Aesthetic Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Feasibility Study: Histological Characterization of Dermal and Subdermal Thermal Coagulation Points in Rhytidectomy Patients After Treatment With the Ulthera\u00ae System", 
        "overall_official": {
            "affiliation": "Sasaki Advanced Aesthetic Medical Center", 
            "last_name": "Gordon Sasaki, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Post\u2010treatment, treated tissue will be resected for histological analysis.", 
            "measure": "To determine the depth of focused thermal injury and thermal injury zone dimensions.", 
            "safety_issue": "Yes", 
            "time_frame": "48 hours post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ulthera, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ulthera, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "November 2013", 
        "why_stopped": "Slow subject enrollment; study to be obtained is no longer required."
    }
}